Please wait a minute...
Journal of ZheJiang University(Medical Science)  2017, Vol. 46 Issue (5): 563-569    DOI: 10.3785/j.issn.1008-9292.2017.10.18
Research progress on genes mutations related to sulfa drug resistance in Pneumocystis jirovecii
WANG Mengyan, ZHU Biao
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Department of Infection Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
Download:   PDF(946KB)
Export: BibTeX | EndNote (RIS)      


Pneumocystis jirovecii pneumonia is an opportunistic infection among immunocompromised people. Studies have found that the increased resistance to sulfa drugs of Pneumocystis jirovecii may be associated with the mutation of dihydropteroate synthase (DHPS) gene and dihydrofolate reductase (DHFR) genes, but the mechanism is still unclear. The mutation of DHPS and DHFR genes may be the result of sulfa drugs selection or spontaneous genetic polymorphism, and it can be acquired from person-to-person transmission. This article reviews the cause, molecular epidemiology of DHPS and DHFR gene mutation, and the relationship between DHPS and DHFR gene mutation and clinical outcomes.

Key wordsDrug resistance,bacterial/genetics      Pneumonia,pneumocystis/physiopathology      Tetrahydrofolate dehydrogenase      Sulfonamides/pharmacology      Genes      Mutation      Review     
Received: 20 February 2017      Published: 25 October 2017
CLC:  R379.9  
Cite this article:

WANG Mengyan, ZHU Biao. Research progress on genes mutations related to sulfa drug resistance in Pneumocystis jirovecii. Journal of ZheJiang University(Medical Science), 2017, 46(5): 563-569.

URL:     OR



关键词: 肺囊虫性/病理生理学,  突变,  基因,  四氢叶酸脱氢酶,  综述,  肺炎,  磺胺类/药理学,  抗药性,  细菌/遗传学 
[[1]]   HUANG L, CROTHERS K, ATZORI C, et al. Dihydropteroate synthase gene mutations in pneumocystis and sulfa resistance[J]. Emerg Infect Dis,2004,10(10):1721-1728.
[[2]]   MESHNICKS R. Drug-resistant pneumocystis carinii[J]. Lancet,1999,354(9187):1318-1319.
[[3]]   HELWEG-LARSEN J, BENFIELD T L, EUGEN-OLSENJ,et al.Effects of mutations in pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia[J]. Lancet,1999,354(9187):1347-1351.
[[4]]   TAYLOR S M, MESHNICK S R, WORODRIA W, et al. Low prevalence of pneumocystis pneumonia (PCP) but high prevalence of pneumocystis dihydropteroate synthase (DHPS) gene mutations in HIV-infected persons in Uganda[J/OL]. PLoS One,2012,7(11):e49991.
[[5]]   HUANG L, WELSH D A, MILLER R F, et al. Pneumocystis jirovecii dihydropteroate synthase gene mutations and human immunodeficiency virus-associated pneumocystis pneumonia[J]. J Eukaryot Microbiol,2006,53 Suppl 1:S114-S116.
[[6]]   HAUSER P M, NAHIMANA A, TAFFE P, et al. Interhuman transmission as a potential key parameter for geographical variation in the prevalence of pneumocystis jirovecii dihydropteroate synthase mutations[J]. Clin Infect Dis,2010,51(4):e28-e33.
[[7]]   DINI L, DU P M, FREAN J, et al. High prevalence of dihydropteroate synthase mutations in Pneumocystis jirovecii isolated from patients with pneumocystis pneumonia in South Africa[J]. J Clin Microbiol,2010,48(6):2016-2021.
[[8]]   OGUIKE M C, FALADE C O, SHU E, et al. Molecular determinants of sulfadoxine-pyrimethamine resistance in plasmodium falciparum in Nigeria and the regional emergence of DHPS 431V[J]. Int J Parasitol Drugs Drug Resist,2016,6(3):220-229.
[[9]]   PORNTHANAKASEM W, RIANGRUNGROJ P, CHITNUMSUB P, et al. Role of plasmodium vivax dihydropteroate synthase polymorphisms in sulfa drug resistance[J]. Antimicrob Agents Chemother,2016,60(8):4453-4463.
[[10]]   QUEENER S F, CODY V, PACE J, et al. Trimethoprim resistance of dihydrofolate reductase variants from clinical isolates of pneumocystis jirovecii[J]. Antimicrob Agents Chemother,2013,57(10):4990-4998.
[[11]]   NAHIMANA A, RABODONIRINA M, BILLE J, et al. Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis[J]. Antimicrob Agents Chemother,2004,48(11):4301-4305.
[[12]]   PONCE C A, CHABÉ M, GEORGE C, et al. High Prevalence of pneumocystis jirovecii dihydropteroate synthase gene mutations in patients with a first episode of pneumocystis pneumonia in Santiago, Chile, and clinical response to trimethoprim-sulfamethoxazole therapy[J]. Antimicrob Agents Chemother,2017,61(2).
[[13]]   MONROY-VACA E X, DE ARMAS Y, ILLNAIT-ZARAGOZÍM T, et al. Prevalence and genotype distribution of pneumocystis jirovecii in Cuban infants and toddlers with whooping cough[J]. J Clin Microbiol,2014,52(1):45-51.
[[14]]   WISSMANN G, MORILLA R, FRIAZA V, et al. Human reservoirs of pneumocystis[J]. Enferm Infecc Microbiol Clin,2010,28(1):38-43.
[[15]]   GIANELLA S, HAEBERLI L, JOOS B, et al. Molecular evidence of interhuman transmission in an outbreak of pneumocystis jirovecii pneumonia among renal transplant recipients[J]. Transpl Infect Dis,2010,12(1):1-10.
[[16]]   ROSTVED A A, SASSI M, KURTZHALS J A, et al. Outbreak of pneumocystis pneumonia in renal and liver transplant patients caused by genotypically distinct strains of pneumocystis jirovecii[J]. Transplantation,2013,96(9):834-842.
[[17]]   CHOUKRI F, MENOTTI J, SARFATI C, et al. Quantification and spread of pneumocystis jirovecii in the surrounding air of patients with Pneumocystis pneumonia[J]. Clin Infect Dis,2010,51(3):259-265.
[[18]]   DAMIANI C, CHOUKRI F, LE G S, et al. Possible nosocomial transmission of pneumocystis jirovecii[J]. Emerg Infect Dis,2012,18(5):877-878.
[[19]]   VALADE S, AZOULAY E, DAMIANI C, et al. Pneumocystis jirovecii airborne transmission between critically ill patients and health care workers[J]. Intensive Care Med,2015,41(9):1716-1718.
[[20]]   RABODONIRINA M, VAILLANT L, TAFFÉ P, et al. Pneumocystis jirovecii genotype associated with increased death rate of HIV-infected patients with pneumonia[J]. Emerg Infect Dis,2013,19(1):21-28.
[[21]]   LONG Y, ZHANG C, SU L, et al. Pneumocystis jirovecii dihydropteroate synthase gene mutations in a group of HIV-negative immunocompromised patients with Pneumocystis pneumonia[J]. Exp Ther Med,2014,8(6):1825-1830.
[[22]]   DIMONTE S, BERRILLI F, D'ORAZI C, et al. Molecular analysis based on mtLSU-rRNA and DHPS sequences of pneumocystis jirovecii from immunocompromised and immunocompetent patients in Italy[J]. Infect Genet Evol,2013,14:68-72.
[[23]]   COSTA M C, ESTEVES F, ANTUNES F, et al. Genetic characterization of the dihydrofolate reductase gene of pneumocystis jirovecii isolates from Portugal[J]. J Antimicrob Chemother,2006,58(6):1246-1249.
[[24]]   DENG X, ZHUO L, LAN Y, et al. Mutational analysis of pneumocystis jirovecii dihydropteroate synthase and dihydrofolate reductase genes in HIV-infected patients in China[J]. J Clin Microbiol,2014,52(11):4017-4019.
[[25]]   MANE A, GUJAR P, CHANDRA J, et al. Pneumocystis jirovecii infection and the associated dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR) mutations in HIV-positive individuals from Pune, India[J]. Mycopathologia,2015,179(1-2):141-145.
[[26]]   PAROBEK C M, JIANG L Y, PATEL J C, et al. Multilocus microsatellite genotyping array for investigation of genetic epidemiology of pneumocystis jirovecii[J]. J Clin Microbiol,2014,52(5):1391-1399.
[[27]]   LE G S, DAMIANI C, PERROT M, et al. Circulation of pneumocystis dihydropteroate synthase mutants in France[J]. Diagn Microbiol Infect Dis,2012,74(2):119-124.
[[28]]   MAGNE D, ANGOULVANT A, BOTTEREL F, et al. Pneumocystosis:a network survey in the Paris area 2003-2008[J]. Eur J Clin Microbiol Infect Dis,2011,30(5):673-675.
[[29]]   ALVAREZ-MARTÍNEZ M J, MIRÓ J M, VALLS M E, et al. Prevalence of dihydropteroate synthase genotypes before and after the introduction of combined antiretroviral therapy and their influence on the outcome of pneumocystis pneumonia in HIV-1-infected patients[J]. Diagn Microbiol Infect Dis,2010,68(1):60-65.
[[30]]   SHEIKHOLESLAMI M F, SADRAEI J, FARNIA P, et al. Dihydropteroate synthase gene mutation rates in pneumocystis jirovecii strains obtained from Iranian HIV-positive and non-HIV-positive patients[J]. Med Mycol,2015,53(4):361-368.
[[31]]   BESER J, DINI L, BOTERO-KLEIVEN S, et al. Absence of dihydropteroate synthase gene mutations in pneumocystis jirovecii isolated from Swedish patients[J]. Med Mycol,2012,50(3):320-323.
[[32]]   YOON C, SUBRAMANIAN A, CHI A, et al. Dihydropteroate synthase mutations in pneumocystis pneumonia:impact of applying different definitions of prophylaxis, mortality endpoints and mutant in a single cohort[J]. Med Mycol,2013,51(6):568-575.
[[33]]   ALVAREZ-MARTÍNEZ M J, MORENO A, MIRÓ J M, et al. Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era:prevalence of dihydropteroate synthase mutations and prognostic factors of mortality[J]. Diagn Microbiol Infect Dis,2008,62(1):34-43
[[34]]   MUÑOZ C, ZULUAGA A, RESTREPO A, et al. Molecular diagnosis and detection of pneumocystis jirovecii DHPS and DHFR genotypes in respiratory specimens from Colombian patients[J]. Diagn Microbiol Infect Dis,2012,72(3):204-213.
[[35]]   KIM T, LEE S O, HONG H L, et al. Clinical characteristics of hospital-onset pneumocystis pneumonia and genotypes of pneumocystis jirovecii in a single tertiary centre in Korea[J]. BMC Infect Dis,2015,15:102.
[[36]]   SINGH Y, MIRDHA B R, GULERIA R, et al. Molecular detection of DHFR gene polymorphisms in pneumocystis jirovecii isolates from Indian patients[J]. J Infect Dev Ctries,2015,9(11):1250-1256.
[[37]]   SIRIPATTANAPIPONG S, LEELAYOOVA S, MUNGTHIN M, et al. Study of DHPS and DHFR genes of pneumocystis jirovecii in Thai HIV-infected patients[J]. Med Mycol,2008,46(4):389-392.
[[38]]   NAGAMORI K, KATAYAMA T, KUMAGAI M. A case of cutaneous myiasis due to dermatobia hominis in Japan[J]. J Infect Chemother,2007,13(4):255-257.
[[39]]   MONTESINOS I, DELFORGE M L, AJJAHAM F, et al. Evaluation of a new commercial real-time PCR assay for diagnosis of pneumocystis jirovecii pneumonia and identification of dihydropteroate synthase (DHPS) mutations[J]. Diagn Microbiol Infect Dis,2017,87(1):32-36.
[[40]]   VAN HAL S J, GILGADO F, DOYLE T, et al. Clinical significance and phylogenetic relationship of novel Australian pneumocystis jirovecii genotypes[J]. J Clin Microbiol,2009,47(6):1818-1823.
[[41]]   MOUKHLIS R, BOYER J, LACUBE P, et al. Linking pneumocystis jiroveci sulfamethoxazole resistance to the alleles of the DHPS gene using functional complementation in saccharomyces cerevisiae[J]. Clin Microbiol Infect,2010,16(5):501-507.
[[42]]   CODY V, PACE J, PIRAINO J, et al. Crystallographic analysis reveals a novel second binding site for trimethoprim in active site double mutants of human dihydrofolate reductase[J]. J Struct Biol,2011,176(1):52-59.
[[43]]   CODY V, PACE J, QUEENER S F, et al. Kinetic and structural analysis for potent antifolate inhibition of pneumocystis jirovecii, pneumocystis carinii, and human dihydrofolate reductases and their active-site variants[J]. Antimicrob Agents Chemother,2013,57(6):2669-2677.
[1] XU Jingjing, TAN Yanbin, ZHANG Minming. Medical imaging in tumor precision medicine: opportunities and challenges[J]. Journal of ZheJiang University(Medical Science), 2017, 46(5): 455-461.
[2] PAN Jingying, HE Mengye, KE Wei, HU Menglin, WANG Meifang, SHEN Peng. Advances on correlation of PET-CT findings with breast cancer molecular subtypes, treatment response and prognosis[J]. Journal of ZheJiang University(Medical Science), 2017, 46(5): 473-480.
[3] ZHANG Siying, CHEN Feng. Research progress of CT/MRI parametric response map in precision evaluation of therapeutic response of cancer patients[J]. Journal of ZheJiang University(Medical Science), 2017, 46(5): 468-472.
[4] PAN Yao, CHEN Jieyu, YU Risheng. Accurate imaging diagnosis and evaluation of pancreatic cancer[J]. Journal of ZheJiang University(Medical Science), 2017, 46(5): 462-467.
[5] GE Yumei, CHEN Xuebo, HUANG Yanying, LYU Huoyang, ZHAO Zhao, ZHOU Yonglie. Drug resistance and protoporphyrin ferrochelatase of Ralstonia mannitolilytica[J]. Journal of ZheJiang University(Medical Science), 2017, 46(4): 413-420.
[6] LI Yandie, LU Meiping. Progress on the study of NLRP3 inflammasome in autoinflammatory diseases of children[J]. Journal of ZheJiang University(Medical Science), 2017, 46(4): 449-453.
[7] WANG Liya, QIAN Yeqing, JIN Fan. Research progress on the safety of offsprings conceived by assisted reproductive technology[J]. Journal of ZheJiang University(Medical Science), 2017, 46(3): 279-284.
[8] YAN Kai, JIN Fan. Advances on prenatal diagnosis of birth defects associated with genetic disorders[J]. Journal of ZheJiang University(Medical Science), 2017, 46(3): 227-232.
[9] TANG Minyue, ZHU Yimin. The involvement of galectin-1 in implantation and pregnancy maintenance at the maternal-fetal interface[J]. Journal of ZheJiang University(Medical Science), 2017, 46(3): 321-327.
[10] FU Xiaohua, XU Weihai, QIU Shengchun, SHU Jing. Research progress on the relationship of brown adipose tissue with polycystic ovary syndrome[J]. Journal of ZheJiang University(Medical Science), 2017, 46(3): 315-320.
[11] FU Yanling, ZHU Yimin. Potential clinical application of Kisspeptin in reproductive endocrinology[J]. Journal of ZheJiang University(Medical Science), 2017, 46(3): 328-333.
[12] QIAN Yeqing, WANG Liya, LUO Yuqin, YAN Kai, DONG Minyue, JIN Fan. Advances in the application of high-throughput sequencing in clinical genetics[J]. Journal of ZheJiang University(Medical Science), 2017, 46(3): 334-337.
[13] SHEN Dan, WANG Fangfang, JIANG Zhou, QU Fan. Long-term effects of polycystic ovary syndrome on the offspring[J]. Journal of ZheJiang University(Medical Science), 2017, 46(3): 300-304.
[14] HE Yujie,PAN Jianping. Progress on mechanisms for pathogensto evade NOD-like receptor and Toll-like receptor signaling pathways[J]. Journal of ZheJiang University(Medical Science), 2017, 46(2): 218-224.
[15] GUO Fengliang,TANG Guping,HU Qinglian. Advances in nanoparticle-targeting tumor associated macrophages for cancer imaging and therapy[J]. Journal of ZheJiang University(Medical Science), 2017, 46(2): 167-172.